In a recent study, survival was 92.9 percent at five years<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 24, 2023 (HealthDay News) — In low-risk patients, long-term survival following surgical aortic valve replacement (SAVR) remains excellent, according to a study published online\u00a0Oct. 17 in the\u00a0Annals of Thoracic Surgery<\/em>.<\/p>\n Vinod H. Thourani, M.D.,\u00a0from Piedmont Healthcare in Atlanta, and colleagues examined long-term, real-world outcomes of 42,586 low-risk patients undergoing SAVR (2011 to 2019).<\/p>\n The researchers found that the mean predicted risk for mortality (PROM) was 1.9 percent. In a time-to-event analysis, all-cause mortality was 2.6 percent at one year, 4.5 percent at three years, 7.1 percent at five years, and 12.4 percent at eight years. Survival was significantly better for patients with lower PROM, younger versus older age, and higher versus lower left ventricular ejection fraction. The eight-year survival following SAVR was 95 percent when PROM was less than 1 percent or the patient age was younger than 75 years.<\/p>\n These contemporary longitudinal data serve to aid in the balanced interpretation of current and future trials comparing SAVR and transcatheter aortic valve replacement and may assist in the clinical decision-making process for patients of lower surgical risk, the authors write.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n